AXTI reports Q1 2026 results tomorrow evening carrying one of the most aggressive analyst re-ratings in its recent history — and a short base that has been quietly rebuilt into the event.
Wedbush's Matt Bryson moved his price target from $28 to $80 today, keeping his Outperform rating intact. That is a near-tripling of the target in a single action, filed the day before the print. The stock closed at $68.71 on Tuesday, meaning Wedbush is now pointing to roughly 16% upside from current levels. For context, Bryson had only raised the target to $28 in February — itself a more than three-fold increase from the prior $8.50. The Street's average target now rests at $67.75, almost exactly at the market price, implying little consensus buffer either way.
The short setup is the counterweight worth watching. SI as a percentage of free float climbed from 10.6% on April 23 to 12.8% by April 28 — a near 21% jump in just three sessions. Over the full month, short interest has risen roughly 25%. That is a meaningful rebuild ahead of an event that, last time around, sent the stock up 26% the next day and 58% over the following five sessions. ORTEX's short score has pulled back from a recent peak of 57 on April 16 to 48.9 now, suggesting the most aggressive short-positioning has already softened — but the absolute level of float on loan remains elevated for a name of this size. Crucially, the borrow market itself is not signalling any urgency: cost to borrow is a modest 0.41%, down 12% on the week, and availability is loose. Short sellers have ample room to add or cover without friction.
Options traders are not taking a strong directional stance. The put/call ratio sits at 0.41, virtually identical to its 20-day mean of 0.42, with a z-score of essentially zero. That is a neutral read — no unusual hedging demand, no obvious call buying surge ahead of earnings. Given the outsized moves this stock has historically delivered around results, the muted options positioning stands out against the elevated short interest.
The bull case heading into tomorrow rests heavily on operating leverage. Gross margins expanded sharply in recent quarters — from 8.2% to over 22% — driven by volume recovery in GaAs for wireless RF and accelerating optics revenue. EPS momentum scores rank in the 96th and 100th percentiles over 30 and 90 days respectively, and the company has beaten estimates 77% of the time on a recent-surprise basis. Bears point to InP (Indium Phosphide) revenue declines — down 39% quarter-over-quarter in the most recent report — and ongoing export permit challenges that could constrain top-line recovery. B. Riley's Dave Kang sits at Neutral with a $21 target, a significant discount to both the market price and Wedbush's revised view. That gap between the two most active analyst voices on this name is wide enough to reflect a genuine debate about the pace of the revenue recovery.
One structural context item: AXT completed a public offering this month and then exercised the over-allotment option, raising an additional $82.5 million. The equity raise dilutes existing holders but strengthens the balance sheet ahead of what management has described as an expanding revenue runway. Meanwhile, insider activity from March tells a more cautious story — the CEO, CFO, and Lead Independent Director all sold shares between March 9 and March 13 at prices ranging from roughly $36 to $51. Those sales occurred well below the current $68.71 close, meaning insiders who sold last month left substantial gains on the table. That does not change the near-term setup, but it does suggest conviction at the board level has not kept pace with the stock's ascent.
What to watch in tomorrow's print: whether InP export licence progress is concrete enough to justify a revenue trajectory that the Wedbush target implies, and whether gross margin expansion can hold above 20% as volume mix shifts — the answer will determine whether the 26%-plus post-earnings gap of last quarter has a realistic repeat.
See the live data behind this article on ORTEX.
Open AXTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
